NASDAQ:ABVX Abivax Q3 2025 Earnings Report $118.33 -1.13 (-0.94%) As of 11:12 AM Eastern This is a fair market value price provided by Massive. Learn more. ProfileEarnings HistoryForecast Abivax EPS ResultsActual EPS-$2.46Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AAbivax Revenue ResultsActual Revenue($4.92) millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AAbivax Announcement DetailsQuarterQ3 2025Date12/15/2025TimeAfter Market ClosesConference Call DateMonday, December 15, 2025Conference Call Time11:45AM ETUpcoming EarningsAbivax's Q2 2026 earnings is estimated for Monday, September 21, 2026, based on past reporting schedules, with a conference call scheduled at 11:40 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Q2 2026 Earnings ReportConference Call ResourcesPress Release (6-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsEarnings Release(6-K) Abivax Earnings HeadlinesAbivax Announces Positive Pre-NDA Interaction with the FDA for ObefazimodJuly 30, 2026 | markets.businessinsider.comABIVAX Société Anonyme (ENXTPA:ABVX) Adds Commercial Leaders, Is The Upside Already Priced In?July 26, 2026 | finance.yahoo.comWashington Is Broke—Could YOUR Savings Be Next?The Department of Justice recently argued in court that cash is not legally property, raising new questions for savers as federal debt continues to climb. Your IRA, 401k, and bank accounts are not hidden from view, prompting some Americans to look for ways to keep more control over their own wealth. A free information kit outlines three strategies people are considering to help shield their savings from future policy changes.September 10 at 1:00 AM | Priority Gold (Ad)Abivax (ENXTPA:ABVX) Adds Commercial Leaders And Signs Valerio R And D DealJuly 25, 2026 | finance.yahoo.comAbivax Strengthens Commercial Capabilities With Strategic Leadership AppointmentsJuly 23, 2026 | finance.yahoo.comAbivax: Obefazimod Goes The Distance And So Does My Buy RatingJuly 16, 2026 | seekingalpha.comSee More Abivax Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Abivax? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Abivax and other key companies, straight to your email. Email Address About AbivaxFounded in 2013 and headquartered in Paris, France, Abivax (NASDAQ:ABVX) is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles. Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders. This small molecule has completed Phase 2 studies in rheumatoid arthritis and ulcerative colitis, demonstrating promising efficacy signals and a favorable tolerability profile. In addition, Abivax is exploring obefazimod’s antiviral potential in early-stage programs targeting chronic viral infections, including HIV and hepatitis B. With operations in Europe and strategic development activities in the United States, Abivax collaborates with academic institutions and research centers to advance its pipeline. The company is led by a management team with deep expertise in biotechnology development and regulatory affairs. Under the leadership of CEO Pascal Mélin, Abivax pursues its mission to bring innovative, host-targeted therapies to patients worldwide. View Abivax ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Casey’s Post-Earnings Drop May Give Investors a Better Entry Into a Quality RetailerCathie Wood Trimmed Palantir, But the Bigger Story Is Still ValuationVictoria’s Secret’s Comeback Is Real—The Stock’s Problem Is DifferentIntel’s ASML Milestone Gives Investors a New Reason to Revisit the StockAnalog Devices Shows Why AI Is Not the Only Story Driving Chip DemandDefense, Solar, and Refining Stocks Split as the Iran Conflict Raises Energy RiskLithia’s Record Quarter Keeps the Bull Case Alive Upcoming Earnings Cintas (9/23/2026)Costco Wholesale (9/24/2026)Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/8/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
